Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Adenocarcinoma of Lung
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Crizotinib
  • Disease Progression
  • Drug Administration Schedule
  • ErbB Receptors / drug effects
  • ErbB Receptors / genetics*
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Molecular Targeted Therapy / methods*
  • Mutation* / drug effects
  • Oncogene Proteins, Fusion / drug effects
  • Oncogene Proteins, Fusion / genetics*
  • Protein Kinase Inhibitors / administration & dosage
  • Pyrazoles / administration & dosage
  • Pyridines / administration & dosage
  • Quinazolines / administration & dosage
  • Treatment Outcome

Substances

  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Quinazolines
  • Crizotinib
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib